Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Daolin Tang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1903-6180; OpenAlex author ID A5055468442; NIH RePORTER profile ID 10614095. Sources: OpenAlex.

Their work

Papers
28 (first author 3, last author 11)
Trials
0
Grants
2
Labs led
3
Collaborators
38
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper, 1 grant · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 9 papers · 2022: 1 paper · 2023: 3 papers, 1 grant · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 28

  1. Ferroptosis in pancreatic ductal adenocarcinoma: Mechanisms, tumor biology, and therapeutic opportunities. Last author DOI 10.1016/j.canlet.2026.218788↗
  2. CYP51A1 drives resistance to pH-dependent cell death in pancreatic cancer. Co-author DOI 10.1038/s41467-025-57583-2↗
  3. AGER-dependent macropinocytosis drives resistance to KRAS-G12D-targeted therapy in advanced pancreatic cancer. Co-author DOI 10.1126/scitranslmed.adp4986↗
  4. Cryptotanshinone differentially induces cell death in ATP6V0D1-deficient pancreatic cancer cells. Co-author DOI 10.20517/cdr.2025.103↗
  5. ITCH inhibits alkaliptosis in human pancreatic cancer cells through YAP1-dependent SLC16A1 activation. Co-author DOI 10.1016/j.biocel.2024.106646↗
  6. Macropinocytosis inhibits alkaliptosis in pancreatic cancer cells through fatty acid uptake. Co-author DOI 10.1093/carcin/bgae045↗
  7. ACSS2-mediated NF-κB activation promotes alkaliptosis in human pancreatic cancer cells. Co-author DOI 10.1038/s41598-023-28261-4↗
  8. EP300 promotes ferroptosis via HSPA5 acetylation in pancreatic cancer. Co-author DOI 10.1038/s41598-023-42136-8↗
  9. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Last author DOI 10.1126/scitranslmed.adg3049↗
  10. Heterodimeric RGD-NGR PET Tracer for the Early Detection of Pancreatic Cancer. Co-author DOI 10.1007/s11307-022-01704-6↗
  11. Cellular and molecular mechanisms of perineural invasion of pancreatic ductal adenocarcinoma. Last author DOI 10.1002/cac2.12188↗
  12. MGST1 is a redox-sensitive repressor of ferroptosis in pancreatic cancer cells. Co-author DOI 10.1016/j.chembiol.2021.01.006↗
  13. Targeting ferroptosis in pancreatic cancer: a double-edged sword. Last author DOI 10.1016/j.trecan.2021.04.005↗
  14. Cell death in pancreatic cancer: from pathogenesis to therapy. Last author DOI 10.1038/s41575-021-00486-6↗
  15. Regulation and function of autophagy in pancreatic cancer. Last author DOI 10.1080/15548627.2020.1847462↗
  16. The dark side of ferroptosis in pancreatic cancer. Last author DOI 10.1080/2162402x.2020.1868691↗
  17. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer. Last author DOI 10.1136/gutjnl-2019-320441↗
  18. Mitophagy in Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.616079↗
  19. The Art of War: Ferroptosis and Pancreatic Cancer. Last author DOI 10.3389/fphar.2021.773909↗
  20. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Co-author DOI 10.1158/1078-0432.ccr-19-4042↗
  21. The Dual Role of HMGB1 in Pancreatic Cancer. First author DOI 10.1097/jp9.0000000000000002↗
  22. RAGE-specific single chain Fv for PET imaging of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0192821↗
  23. Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Last author DOI 10.1038/cr.2017.51↗
  24. The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer. Co-author DOI 10.1038/cgt.2015.21↗
  25. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and develop… First author DOI 10.1097/mpa.0000000000000298↗
  26. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. Co-author DOI 10.1038/cddis.2014.445↗
  27. Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e3182854ab0↗
  28. Autophagy in pancreatic cancer pathogenesis and treatment. First author PMID 22860230↗

Grants 2

  1. Mitophagy in Tumor Microenvironment R01CA160417↗
  2. Career Development Award: Daolin Tang (HMGB1 in pancreatic cancer) AWARD pancan:2013-daolin-tang-md-phd-career-development-award-daolin-tang-hmg

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rui Kang · 22 shared papers, 2012–2026 · strength 3.98
  2. Jiao Liu · 6 shared papers, 2023–2025 · strength 1.44
  3. Fangquan Chen · 5 shared papers, 2024–2025 · strength 1.26
  4. Herbert J. Zeh · 11 shared papers, 2013–2025 · strength 1.11
  5. Yangchun Xie · 5 shared papers, 2017–2026 · strength 1.02
  6. Xin Chen · 4 shared papers, 2021–2023 · strength 0.70
  7. Changfeng Li · 2 shared papers, 2025 · strength 0.55
  8. Michael T. Lotze · 8 shared papers, 2013–2021 · strength 0.53
  9. Xiutao Cai · 2 shared papers, 2024–2025 · strength 0.49
  10. Feimei Kuang · 2 shared papers, 2021–2023 · strength 0.41
  11. Jiao Liu · 2 shared papers, 2021 · strength 0.39
  12. Jiao Liu · 2 shared papers, 2021–2023 · strength 0.39
  13. Yuanda Liu · 1 shared paper, 2025 · strength 0.25
  14. Dongwen Que · 1 shared paper, 2023 · strength 0.24
  15. Jiao Liu · 1 shared paper, 2023 · strength 0.24
  16. Jingbo Li · 1 shared paper, 2021 · strength 0.22
  17. Brian A. Boone · 3 shared papers, 2015–2020 · strength 0.22
  18. Yuan Wang · 1 shared paper, 2023 · strength 0.22
  19. Dexing Zeng · 2 shared papers, 2017–2022 · strength 0.22
  20. David L. Bartlett · 3 shared papers, 2014–2020 · strength 0.19
  21. Jingbo Li · 1 shared paper, 2023 · strength 0.18
  22. Brent R. Stockwell · 1 shared paper, 2023 · strength 0.18
  23. Jingbo Li · 1 shared paper, 2021 · strength 0.16
  24. Yongkang Gai · 1 shared paper, 2022 · strength 0.16
  25. Lingyi Sun · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.